NCT01533714View on ClinicalTrials.gov

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

January 26, 2012

Primary Completion Date

November 27, 2013

Study Completion Date

November 29, 2013

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

CDP6038 (olokizumab)

Biological/Vaccine: CDP6038 (olokizumab) 100 mg/mL solution for subcutaneous (sc) injection

Trial Locations (32)

Unknown

102, Chiba

114, Fukuoka

115, Fukuoka

113, Hiroshima

120, Kakogawa

118, Kumamoto

116, Kurume

122, Matsuyama

107, Nagaoka

110, Nagoya

103, Narita

112, Okayama

119, Ōita

100, Sapporo

117, Sasebo

123, Tokyo

101, Tomakomai

108, Tonami

111, Tsu

105, Yokohama

104, Yotukaido

200, Daejeon

201, Junggu

202, Seongdong-Gu

203, Seoul

204, Seoul

301, Taichung

306, Taichung

307, Taichung

302, Taipei

308, Taipei

309, Taipei

Sponsors

Collaborators (1)

R-Pharm
All Listed Sponsors
collaborator

R-Pharm

INDUSTRY

lead

UCB BIOSCIENCES, Inc.

INDUSTRY